WHAT IS CLAIMED IS:

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

B^1 is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^1 is selected from the group consisting of an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^2 is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R^{3a} and R^{3b} are independently selected from the group consisting of hydrogen, deuterium, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{1-6} haloalkyl and aryl(C_{1-6} alkyl); or R^{3a} and R^{3b} are taken together to form an optionally substituted C_{3-6} cycloalkyl;

R^4 is selected from the group consisting of hydrogen, azido, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^5 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{10}$ and $-OC(=O)R^{11}$;

R^6 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{12}$ and $-OC(=O)R^{13}$;

R^7 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{14}$ and $-OC(=O)R^{15}$;

or R^6 and R^7 are both oxygen atoms and linked together by a carbonyl group;

R^8 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{16}$ and $-OC(=O)R^{17}$;

R^9 is selected from the group consisting of hydrogen, azido, cyano, an optionally substituted C_{1-6} alkyl and $-OR^{18}$;

R^{10}, R^{12}, R^{14}, R^{16} and R^{18} are independently selected from the group consisting of hydrogen and an optionally substituted C_{1-6} alkyl; and

R^{11}, R^{13}, R^{15} and R^{17} are independently an optionally substituted C_{1-6} alkyl or an optionally substituted C_{3-6} cycloalkyl;

with the proviso that when R^{3a}, R^{3b}, R^4, R^5, R^7, R^8 and R^9 are all hydrogen, then R^6 is not azido.

2. The compound of Claim 1, wherein R^8 is hydrogen.

3. The compound of Claim 1 or 2, wherein R^2 is an optionally substituted aryl.

4. The compound of Claim 3, wherein the optionally substituted aryl is an optionally substituted phenyl.

5. The compound of Claim 3, wherein the optionally substituted aryl is an optionally substituted naphthyl.

6. The compound of Claim 1 or 2, wherein R^2 is an optionally substituted heteroaryl.

7. The compound of any one of Claims 1 to 6, wherein R^1 is an optionally substituted N–linked α-amino acid.

8. The compound of any one of Claims 1 to 6, wherein R^1 is an optionally substituted N–linked α-amino acid ester derivative.

9. The compound of any one of Claims 1 to 6, wherein R^1 is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof.

10. The compound of Claim 9, wherein R^1 is selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester, and leucine isopropyl ester.

11. The compound of Claim 10, wherein R^1 is alanine isopropyl ester.

12. The compound of any one of Claims 1 to 6, wherein R^1 has the structure  wherein R^{22} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{23} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{24} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{23} and R^{24} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

13. The compound of Claim 12, wherein R^{23} is an optionally substituted C_{1-6}-alkyl.

14. The compound of Claim 13, wherein the optionally substituted C_{1-6}-alkyl is methyl.

15. The compound of any one of Claims 12 to 14, wherein the optionally substituted C_{1-6}-alkyl is substituted with one or more substituents selected from the group consisting of N-amido, mercapto, alkylthio, an optionally substituted aryl, hydroxy, an optionally substituted heteroaryl, C-carboxy, and amino.

16. The compound of any one of Claims 12 to 15, wherein R^{24} is hydrogen.

17. The compound of any one of Claims 12 to 16, wherein R^{22} is an optionally substituted C_{1-6} alkyl.

18. The compound of any one of Claims 12 to 16, wherein R^{22} is an optionally substituted C_{3-6} cycloalkyl.

19. The compound of Claim 12, wherein  is  ,  ,  ,






or .

20. The compound of Claim 19, wherein  is  .

21. A compound of Formula (I), or a thio-monophosphate thereof, or a pharmaceutically acceptable salt of the foregoing:


(I)

wherein:

B^1 is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^1 is O^- or OH;

R^2 is  , wherein R^{19}, R^{20} and R^{21} are independently absent or hydrogen, and n is 0 or 1;

R^{3a} and R^{3b} are independently selected from the group consisting of hydrogen, deuterium, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally

substituted C_{1-6} haloalkyl and aryl(C_{1-6} alkyl); or R^{3a} and R^{3b} are taken together to form an optionally substituted C_{3-6} cycloalkyl;

R^4 is selected from the group consisting of hydrogen, azido, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^5 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{10}$ and $-OC(=O)R^{11}$;

R^6 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{12}$ and $-OC(=O)R^{13}$;

R^7 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{14}$ and $-OC(=O)R^{15}$;

or R^6 and R^7 are both oxygen atoms and linked together by a carbonyl group;

R^8 is selected from the group consisting of halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{16}$ and $-OC(=O)R^{17}$;

R^9 is selected from the group consisting of hydrogen, azido, cyano, an optionally substituted C_{1-6} alkyl and $-OR^{18}$;

R^{10}, R^{12}, R^{14}, R^{16} and R^{18} are independently selected from the group consisting of hydrogen and an optionally substituted C_{1-6} alkyl; and

R^{11}, R^{13}, R^{15} and R^{17} are independently an optionally substituted C_{1-6} alkyl or an optionally substituted C_{3-6} cycloalkyl;

with the proviso that when R^{3a}, R^{3b}, R^4, R^5, R^7 and R^9 are all hydrogen, then R^6 is not azido.

22. The compound of Claim 21, wherein n is 1.

23. The compound of Claim 21, wherein n is 0.

24. The compound of any one of Claims 1 or 3 to 23, wherein R^8 is an optionally substituted C_{1-6} alkyl.

25. The compound of any one of Claims 1 or 3 to 23, wherein R^8 is an unsubstituted C_{1-6} alkyl.

26. The compound of Claim 25, wherein R^8 is methyl.

27. The compound of any one of Claims 1 or 3 to 23, wherein R^8 is halogen.

28. The compound of any one of Claims 1 to 27, wherein R^{3a} and R^{3b} are both hydrogen.

29. The compound of any one of Claims 1 to 27, wherein at least one of R^{3a} and R^{3b} is an optionally substituted C_{1-6}-alkyl; and the other of R^{3a} and R^{3b} is hydrogen.

30. The compound of any one of Claims 1 to 29, wherein R^4 is hydrogen.

31. The compound of any one of Claims 1 to 30, wherein R^5 is hydrogen.

32. The compound of any one of Claims 1 to 31, wherein R^6 is $-OR^{12}$.

33. The compound of Claim 32, wherein R^{12} is hydrogen.

34. The compound of Claim 32, wherein R^{12} is an optionally substituted C_{1-6} alkyl.

35. The compound of any one of Claims 1 to 31, wherein R^6 is $-OC(=O)R^{13}$.

36. The compound of any one of Claims 1 to 35, wherein R^7 is $-OR^{14}$.

37. The compound of Claim 36, wherein R^{14} is hydrogen.

38. The compound of Claim 36, wherein R^{14} is an optionally substituted C_{1-6} alkyl.

39. The compound of any one of Claims 1 to 35, wherein R^7 is $-OC(=O)R^{15}$.

40. The compound of any one of Claims 1 to 35, wherein R^7 is halogen.

41. The compound of any one of Claims 1 to 31, wherein R^6 and R^7 are both oxygen atoms and linked together by a carbonyl group.

42. The compound of any one of Claims 1 to 41, wherein R^9 is hydrogen.

43. The compound of any one of Claims 1 to 42, wherein B^1 is selected from the group consisting of:


,

,

,

,

and

;

wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is selected from the group consisting of hydrogen, $-C(=O)R^{K2}$ and $-C(=O)OR^{L2}$;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{M2}$ and $-C(=O)OR^{N2}$;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is selected from the group consisting of hydrogen, $-C(=O)R^{P2}$ and $-C(=O)OR^{Q2}$;

R^{D2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{E2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{R2}$ and $-C(=O)OR^{S2}$;

R^{F2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

Y^2 is N or CR^{I2}, wherein R^{I2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{2-6}-alkenyl and an optionally substituted C_{2-6}-alkynyl;

R^{G2} is an optionally substituted C_{1-6} alkyl;

R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is independently selected from the group consisting of hydrogen, $-C(=O)R^{U2}$ and $-C(=O)OR^{V2}$, and

R^{K2}, R^{L2}, R^{M2}, R^{N2}, R^{P2}, R^{Q2}, R^{R2}, R^{S2}, R^{U2} and R^{V2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{3-6} cycloalkynyl, C_{6-10} aryl, heteroaryl, heteroalicyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl) and heteroalicyclyl(C_{1-6} alkyl).

44. The compound of Claim 43, wherein B^1 is  or  .

45. The compound of Claim 43, wherein B^1 is  .

46. The compound of Claim 43, wherein B^1 is  .

47. The compound of Claim 43, wherein B^1 is  .

48. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,



,



,







,



,













,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

and , or a pharmaceutically acceptable salt of the foregoing.

49. The compound of Claim 1, wherein the compound of Formula (I) is


, or a pharmaceutically acceptable salt thereof.

50. The compound of Claim 1, wherein the compound of Formula (I) is


, or a pharmaceutically acceptable salt thereof.

51. The compound of Claim 50, wherein the compound of Formula (I) is


, or a pharmaceutically acceptable salt thereof.

52. The compound of Claim 50, wherein the compound of Formula (I) is


, or a pharmaceutically acceptable salt thereof.

53. The compound of Claim 1, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

54. The compound of Claim 53, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

55. The compound of Claim 53, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

56. The compound of Claim 1, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

57. The compound of Claim 21, wherein the compound of Formula (I) is selected from the group consisting of:


,


,


,


,


and , or a pharmaceutically acceptable salt of the foregoing.

58. The compound of Claim 57, wherein the compound of Formula (I) is:


, or a pharmaceutically acceptable salt thereof.

59. The compound of Claim 57, wherein the compound of Formula (I) is:


, or a pharmaceutically acceptable salt thereof.

60. The compound of Claim 57, wherein the compound of Formula (I) is:


, or a pharmaceutically acceptable salt thereof.

61. The compound of Claim 57, wherein the compound of Formula (I) is:


, or a pharmaceutically acceptable salt thereof.

62. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

63. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 for preparing a medicament for ameliorating or treating an HCV infection.

64. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 for preparing a medicament for inhibiting NS5B polymerase activity of hepatitis C virus.

65. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 for preparing a medicament for inhibiting replication of a hepatitis C virus.

66. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 for preparing a medicament for contacting a cell infected with a hepatitis C virus, whereby ameliorating or treating the hepatitis C viral infection.

67. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 in the preparation of a medicament for ameliorating or treating a viral infection, wherein the medicament is manufactured for use in combination with one or more agents selected from the group consisting of an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (BB) and a compound of Formula (DD), or a pharmaceutically acceptable salt any of the aforementioned compounds.

68. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 in the preparation of a medicament for contacting a cell infected with a viral infection, wherein the medicament is manufactured for use in combination with one or more agents selected from the group consisting of an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (BB) and a compound of Formula (DD), or a pharmaceutically acceptable salt any of the aforementioned compounds.

69. The use of Claim 67 or 68, wherein the one or more agents are selected from the group consisting of Compounds 1001-1014, 2001-2010, 3001-3008, 4001-4005, 5001-5002, 8000-8012 and 9000, or a pharmaceutically acceptable salt of any of the aforementioned compounds.

70. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is Compound 4001,  , or a pharmaceutically acceptable salt thereof.

71. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is Compound 4001,  , or a pharmaceutically acceptable salt thereof.

72. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is Compound 1013,  , or a pharmaceutically acceptable salt thereof.

73. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable

salt thereof; and one or more agents is Compound 1013,  , or a pharmaceutically acceptable salt thereof.

74. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is Compound 4001,  , or a pharmaceutically acceptable salt thereof.

75. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is Compound 4001,



, or a pharmaceutically acceptable salt thereof.

76. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is Compound 1013,  , or a pharmaceutically acceptable salt thereof.

77. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt

thereof; and one or more agents is Compound 1013,  , or a pharmaceutically acceptable salt thereof.

CLAIMS

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

B^1 is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^1 is selected from the group consisting of an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester;

R^2 is selected from an optionally substituted aryl or an optionally substituted heteroaryl;

R^{3a} and R^{3b} are independently selected from the group consisting of hydrogen, deuterium, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{1-6} haloalkyl and aryl(C_{1-6} alkyl); or R^{3a} and R^{3b} are taken together to form an optionally substituted C_{3-6} cycloalkyl;

R^4 is selected from the group consisting of hydrogen, azido, an optionally substituted C_{1-6} alkyl, and an optionally substituted C_{2-6} alkynyl;

R^5 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{10}$ and $-OC(=O)R^{11}$;

R^6 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{12}$ and $-OC(=O)R^{13}$;

R^7 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{14}$ and $-OC(=O)R^{15}$;

or R^6 and R^7 are both oxygen atoms and linked together by a carbonyl group;

R^8 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{16}$ and $-OC(=O)R^{17}$;

R^9 is selected from the group consisting of hydrogen, azido, cyano, an optionally substituted C_{1-6} alkyl and $-OR^{18}$;

R^{10}, R^{12}, R^{14}, R^{16} and R^{18} are independently selected from the group consisting of hydrogen and an optionally substituted C_{1-6} alkyl; and

R^{11}, R^{13}, R^{15} and R^{17} are independently an optionally substituted C_{1-6} alkyl or an optionally substituted C_{3-6} cycloalkyl;

with the proviso that when R^{3a}, R^{3b}, R^4, R^5, R^7, R^8 and R^9 are all hydrogen, then R^6 is not azido.

2. The compound of Claim 1, wherein R^8 is hydrogen.

3. The compound of Claim 1 or 2, wherein R^2 is an optionally substituted aryl.

4. The compound of Claim 3, wherein the optionally substituted aryl is an optionally substituted phenyl.

5. The compound of Claim 3, wherein the optionally substituted aryl is an optionally substituted naphthyl.

6. The compound of Claim 1 or 2, wherein R^2 is an optionally substituted heteroaryl.

7. The compound of any one of Claims 1 to 6, wherein R^1 is an optionally substituted N–linked α-amino acid.

8. The compound of any one of Claims 1 to 6, wherein R^1 is an optionally substituted N–linked α-amino acid ester.

9. The compound of any one of Claims 1 to 6, wherein R^1 is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and esters thereof.

10. The compound of Claim 9, wherein R^1 is selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester, and leucine isopropyl ester.

11. The compound of Claim 10, wherein R^1 is alanine isopropyl ester.

12. The compound of any one of Claims 1 to 6, wherein R^1 has the structure



wherein R^{22} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6}

alkyl) and an optionally substituted haloalkyl; R^{23} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{24} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{23} and R^{24} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

13. The compound of Claim 12, wherein R^{23} is an optionally substituted C_{1-6}-alkyl.

14. The compound of Claim 13, wherein the optionally substituted C_{1-6}-alkyl is methyl.

15. The compound of any one of Claims 12 to 14, wherein the optionally substituted C_{1-6}-alkyl is substituted with one or more substituents selected from the group consisting of N-amido, mercapto, alkylthio, an optionally substituted aryl, hydroxy, an optionally substituted heteroaryl, C-carboxy, and amino.

16. The compound of any one of Claims 12 to 15, wherein R^{24} is hydrogen.

17. The compound of any one of Claims 12 to 16, wherein R^{22} is an optionally substituted C_{1-6} alkyl.

18. The compound of any one of Claims 12 to 16, wherein R^{22} is an optionally substituted C_{3-6} cycloalkyl.

19. The compound of Claim 12, wherein  is  ,





 ,

 ,

or  .

20. The compound of Claim 19, wherein  is  .

21. A compound of Formula (I), or a thio-monophosphate thereof, or a pharmaceutically acceptable salt of the foregoing:



(I)

wherein:

B^1 is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^1 is O^- or OH;

R^2 is  , wherein R^{19}, R^{20} and R^{21} are independently absent or hydrogen, and n is 0 or 1;

R^{3a} and R^{3b} are independently selected from the group consisting of hydrogen, deuterium, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally

substituted C_{1-6} haloalkyl and aryl(C_{1-6} alkyl); or R^{3a} and R^{3b} are taken together to form an optionally substituted C_{3-6} cycloalkyl;

R^4 is selected from the group consisting of hydrogen, azido, an optionally substituted C_{1-6} alkyl, and an optionally substituted C_{2-6} alkynyl;

R^5 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{10}$ and $-OC(=O)R^{11}$;

R^6 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{12}$ and $-OC(=O)R^{13}$;

R^7 is selected from the group consisting of hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{14}$ and $-OC(=O)R^{15}$;

or R^6 and R^7 are both oxygen atoms and linked together by a carbonyl group;

R^8 is selected from the group consisting of halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, and $-OC(=O)R^{17}$;

R^9 is selected from the group consisting of hydrogen, azido, cyano, an optionally substituted C_{1-6} alkyl and $-OR^{18}$;

R^{10}, R^{12}, R^{14}, and R^{18} are independently selected from the group consisting of hydrogen and an optionally substituted C_{1-6} alkyl; and

R^{11}, R^{13}, R^{15} and R^{17} are independently an optionally substituted C_{1-6} alkyl or an optionally substituted C_{3-6} cycloalkyl;

with the proviso that when R^{3a}, R^{3b}, R^4, R^5, R^7 and R^9 are all hydrogen, then R^6 is not azido.

22. The compound of Claim 21, wherein n is 1.

23. The compound of Claim 21, wherein n is 0.

24. The compound of any one of Claims 1 or 3 to 23, wherein R^8 is an optionally substituted C_{1-6} alkyl.

25. The compound of any one of Claims 1 or 3 to 23, wherein R^8 is an unsubstituted C_{1-6} alkyl.

26. The compound of Claim 25, wherein R^8 is methyl.

27. The compound of any one of Claims 1 or 3 to 23, wherein R^8 is halogen.

28. The compound of any one of Claims 1 to 27, wherein R^{3a} and R^{3b} are both hydrogen.

29. The compound of any one of Claims 1 to 27, wherein at least one of R^{3a} and R^{3b} is an optionally substituted C_{1-6}-alkyl; and the other of R^{3a} and R^{3b} is hydrogen.

30. The compound of any one of Claims 1 to 29, wherein R^4 is hydrogen.

31. The compound of any one of Claims 1 to 30, wherein R^5 is hydrogen.

32. The compound of any one of Claims 1 to 31, wherein R^6 is $-OR^{12}$.

33. The compound of Claim 32, wherein R^{12} is hydrogen.

34. The compound of Claim 32, wherein R^{12} is an optionally substituted C_{1-6} alkyl.

35. The compound of any one of Claims 1 to 31, wherein R^6 is $-OC(=O)R^{13}$.

36. The compound of any one of Claims 1 to 35, wherein R^7 is $-OR^{14}$.

37. The compound of Claim 36, wherein R^{14} is hydrogen.

38. The compound of Claim 36, wherein R^{14} is an optionally substituted C_{1-6} alkyl.

39. The compound of any one of Claims 1 to 35, wherein R^7 is $-OC(=O)R^{15}$.

40. The compound of any one of Claims 1 to 35, wherein R^7 is halogen.

41. The compound of any one of Claims 1 to 31, wherein R^6 and R^7 are both oxygen atoms and linked together by a carbonyl group.

42. The compound of any one of Claims 1 to 41, wherein R^9 is hydrogen.

43. The compound of any one of Claims 1 to 42, wherein B^1 is selected from the group consisting of:



,


,


,


,


and


;

wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is selected from the group consisting of hydrogen, $-C(=O)R^{K2}$ and $-C(=O)OR^{L2}$;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{M2}$ and $-C(=O)OR^{N2}$;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is selected from the group consisting of hydrogen, $-C(=O)R^{P2}$ and $-C(=O)OR^{Q2}$;

R^{D2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{E2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{R2}$ and $-C(=O)OR^{S2}$;

R^{F2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

Y^2 is N or CR^{I2}, wherein R^{I2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{2-6}-alkenyl and an optionally substituted C_{2-6}-alkynyl;

R^{G2} is an optionally substituted C_{1-6} alkyl;

R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is independently selected from the group consisting of hydrogen, $-C(=O)R^{U2}$ and $-C(=O)OR^{V2}$, and

R^{K2}, R^{L2}, R^{M2}, R^{N2}, R^{P2}, R^{Q2}, R^{R2}, R^{S2}, R^{U2} and R^{V2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{3-6} cycloalkynyl, C_{6-10} aryl, heteroaryl, heteroalicyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl) and heteroalicyclyl(C_{1-6} alkyl).

44. The compound of Claim 43, wherein B^1 is  or  .

45. The compound of Claim 43, wherein B^1 is  .

46. The compound of Claim 43, wherein B^1 is  .

47. The compound of Claim 43, wherein B^1 is  .

48. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,
,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

and , or a pharmaceutically acceptable salt of the foregoing.

49. The compound of Claim 1, wherein the compound of Formula (I) is


, or a pharmaceutically acceptable salt thereof.

50. The compound of Claim 1, wherein the compound of Formula (I) is


, or a pharmaceutically acceptable salt thereof.

51. The compound of Claim 50, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

52. The compound of Claim 50, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

53. The compound of Claim 1, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

54. The compound of Claim 53, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

55. The compound of Claim 53, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

56. The compound of Claim 1, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

57. The compound of Claim 21, wherein the compound of Formula (I) is selected from the group consisting of:



,



,



,



,



and , or a pharmaceutically acceptable salt of the foregoing.

58. The compound of Claim 57, wherein the compound of Formula (I) is:



, or a pharmaceutically acceptable salt thereof.

59. The compound of Claim 57, wherein the compound of Formula (I) is:



, or a pharmaceutically acceptable salt thereof.

60. The compound of Claim 57, wherein the compound of Formula (I) is:



, or a pharmaceutically acceptable salt thereof.

61. The compound of Claim 57, wherein the compound of Formula (I) is:



, or a pharmaceutically acceptable salt thereof.

62. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

63. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 for preparing a medicament for ameliorating or treating an HCV infection.

64. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 for preparing a medicament for inhibiting NS5B polymerase activity of hepatitis C virus.

65. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 for preparing a medicament for inhibiting replication of a hepatitis C virus.

66. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 for preparing a medicament for contacting a cell infected with a hepatitis C virus, whereby ameliorating or treating the hepatitis C viral infection.

67. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 in the preparation of a medicament for ameliorating or treating a viral infection, wherein the medicament is manufactured for use in combination with one or more agents selected from the group consisting of an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (BB) and a compound of Formula (DD), or a pharmaceutically acceptable salt any of the aforementioned compounds.

68. Use of a compound of any one of Claims 1 to 61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 62 in the preparation of a medicament for contacting a cell infected with a viral infection, wherein the medicament is manufactured for use in combination with one or more agents selected from the group consisting of an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (BB) and a compound of Formula (DD), or a pharmaceutically acceptable salt any of the aforementioned compounds.

69. The use of Claim 67 or 68, wherein the one or more agents are selected from the group consisting of pegylated interferon alpha, pegylated interferon-alpha-2a, pegylated interferon-alpha-2b, interferon alfacon-1, pegylated interferon lambda, interferon lambda 1, interferon lambda 2, consensus interferon, cyclosporin A,  ,  ,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

and

,

or a pharmaceutically acceptable salt of any of the aforementioned compounds.

70. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is  , or a pharmaceutically acceptable salt thereof.

71. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is



, or a pharmaceutically acceptable salt thereof.

72. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is  , or a pharmaceutically acceptable salt thereof.

73. The use of any one of Claims 67 to 68, wherein the compound of Formula (I) is  , or a pharmaceutically acceptable salt thereof; and one or more agents is  , or a pharmaceutically acceptable salt thereof.

74. The use of any one of Claims 67 to 68, wherein the compound of Formula (I)



is , or a pharmaceutically acceptable salt thereof; and one or more agents is



, or a pharmaceutically acceptable salt thereof.

75. The use of any one of Claims 67 to 68, wherein the compound of Formula (I)



is , or a pharmaceutically acceptable salt thereof; and one or more agents is



, or a pharmaceutically acceptable salt thereof.

76. The use of any one of Claims 67 to 68, wherein the compound of Formula (I)



is , or a pharmaceutically acceptable salt



thereof; and one or more agents is , or a pharmaceutically acceptable salt thereof.

77. The use of any one of Claims 67 to 68, wherein the compound of Formula (I)



is , or a pharmaceutically acceptable salt



thereof; and one or more agents is , or a pharmaceutically acceptable salt thereof.